SOPHiA GENETICS (SOPH) Common Equity (2020 - 2025)

SOPHiA GENETICS has disclosed Common Equity across 6 years of filings, most recently posting $47.1 million for Q4 2025.

• Common Equity for Q4 2025 came in at $47.1 million, down 51.14% year-over-year; the trailing twelve-month figure through Dec 2025 was $47.1 million (down 51.14% YoY), and the FY2025 annual result was $47.1 million, down 51.14% from the prior year.
• Common Equity came in at $47.1 million for Q4 2025 at SOPHiA GENETICS, down from $60.7 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $289.7 million in Q3 2021 to a low of $47.1 million in Q4 2025.
• The 5-year median for Common Equity is $151.4 million (2023), against an average of $153.8 million.
• Across the five-year window, Common Equity soared 220.86% in 2022 and sank 51.14% in 2025, its largest moves.
• SOPHiA GENETICS's Common Equity stood at $275.4 million in 2021, then retreated by 27.33% to $200.1 million in 2022, then decreased by 24.33% to $151.4 million in 2023, then sank by 36.29% to $96.5 million in 2024, then plunged by 51.14% to $47.1 million in 2025.
• The last three Common Equity figures came in at $47.1 million (Q4 2025), $60.7 million (Q3 2025), and $76.7 million (Q2 2025), per Business Quant data.